RIGEL PHARMACEUTICALS INC
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The exhibits listed on the accompanying index to exhibits are filed or incorporated by reference (as stated therein) as part of this Quarterly Report on Form 10-Q.
| | ||
| ExhibitNumber | | Description of Document |
| | | |
| 3.1 | | Amended and Restated Certificate of Incorporation. (1) |
| 3.2 | | Amended and Restated Bylaws. (2) |
| 3.3 | | Certificate of Amendment to the Amended and Restated Certificate of Incorporation. (3) |
| 4.1 | | Form of warrant to purchase shares of common stock. (4) |
| 4.2 | | Specimen Common Stock Certificate. (5) |
| 10.1#˄ | | Asset Purchase Agreement with Blueprint Medicines Corporation, dated February 22, 2024. |
| 10.2#˄ | | Amendment No. 2 to the License and Collaboration Agreement with Eli Lilly and Company, dated March 11, 2024. |
| 10.3#˄ | | Fourth Amendment to the Credit and Security Agreement with MidCap Financial Trust, dated April 11, 2024. |
| 10.4# | | Rigel Pharmaceuticals, Inc. Inducement Plan, as amended. |
| 31.1# | | Certification required by Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act. |
| 31.2# | | Certification required by Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act. |
| 32.1*# | | Certification required by Rule 13a-14(b) or Rule 15d-14(b) of the Exchange Act and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350). |
| 101.INS | | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | | Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL | | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.LAB | | Inline XBRL Taxonomy Extension Labels Linkbase Document. |
| 101.PRE | | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 101.DEF | | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 104 | | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
| # | Filed herewith |
|---|
˄Certain marked information has been redacted from this exhibit pursuant to Item 601(b)(1)(iv) of Regulation S-K because it is both not material and is the type that the registrant treats as private and confidential. An unredacted copy of this exhibit will be furnished supplementally to the SEC upon request.
** The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the registrant for purposes of Section 18 of the Exchange Act.*
| (1) | Filed as an exhibit to Rigel’s Current Report on Form 8-K dated June 24, 2003, and incorporated herein by reference. |
| (2) | Filed as an exhibit to Rigel’s Current Report on Form 8-K dated November 3, 2022, and incorporated herein by reference. |
| (3) | Filed as an exhibit to Rigel’s Current Report on Form 8-K dated May 18, 2018, and incorporated herein by reference. |
| (4) | Filed as an exhibit to Rigel’s Registration Statement on Form S-1 (No. 333-45864), filed on September 15, 2000, as amended, and incorporated herein by reference. |
| (5) | Filed as an exhibit to Rigel’s Current Report on Form 10-K dated June 24, 2003, and incorporated herein by reference. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.